Start your own journey to clinic

Please provide us with a few details so that we can match you with the right expert in your field.

*Required

Thank you, your request has been received.

We're busy connecting you with an expert, who will be in touch as soon as possible.

Oops! Something went wrong while submitting the form. Please try again or email us at webenquiries@conceptlifesciences.com
Poster

Poster

Development of WEE1 inhibitors with selectivity against PLK1

WEE1, regulates the G2/M cell cycle checkpoint, via by phosphorylating of CDK1 (aka Cdc2) at Tyr15, which inhibits CDK1/cyclin B kinase activity. Inhibition of WEE1 overrides DNA damage-induced cell cycle arrest in cells with a malfunctioning G1 checkpoint, leading TP53 mutant cancer cells into mitotic catastrophe (Duda et al, 2016). This makes WEE1 an appealing target for amplifying the impact of chemotherapeutic DNA-damaging therapies. Despite the advancement of the potent WEE1 inhibitor AZD1775 (MK1775) into clinical trials, recent reports suggest unexpected antiproliferative effects, possibly linked to poor kinase selectivity and inhibition of polo-like kinase 1 (PLK1). At Concept Life Sciences , we are dedicated to identifying and developing a highly selective WEE1 tool compound, offering a valuable resource for precise biological research and gaining deeper insights into WEE1's role

Alternatively, search our entire resource library below

Show filters
View all
Category one
Category two
Category three
Category four
Search
Clear
Resource type
Clear
Related service line
Clear
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tag
Showing 0 items